These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 8078530

  • 1. A comparison of budesonide with prednisolone for active Crohn's disease.
    Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, Danielsson A, Goebell H, Thomsen OO, Lorenz-Meyer H.
    N Engl J Med; 1994 Sep 29; 331(13):842-5. PubMed ID: 8078530
    [Abstract] [Full Text] [Related]

  • 2. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T.
    N Engl J Med; 1994 Sep 29; 331(13):836-41. PubMed ID: 8078529
    [Abstract] [Full Text] [Related]

  • 3. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E.
    N Engl J Med; 1998 Aug 06; 339(6):370-4. PubMed ID: 9691103
    [Abstract] [Full Text] [Related]

  • 4. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
    Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K, Schölmerich J.
    Hepatogastroenterology; 1997 Aug 06; 44(14):445-51. PubMed ID: 9164517
    [Abstract] [Full Text] [Related]

  • 5. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
    Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, Schulz HJ, Bär U, Weber A, Gierend M, Ewe K, Schölmerich J.
    Eur J Gastroenterol Hepatol; 1996 Sep 06; 8(9):905-9. PubMed ID: 8889459
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
    Escher JC, European Collaborative Research Group on Budesonide in Paediatric IBD.
    Eur J Gastroenterol Hepatol; 2004 Jan 06; 16(1):47-54. PubMed ID: 15095852
    [Abstract] [Full Text] [Related]

  • 8. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
    Novacek G, Kleinberger M, Vogelsang H, Moser G, Lochs H.
    Z Gastroenterol; 1995 May 06; 33(5):251-4. PubMed ID: 7610692
    [Abstract] [Full Text] [Related]

  • 9. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
    Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW.
    N Engl J Med; 2000 Jun 01; 342(22):1627-32. PubMed ID: 10833208
    [Abstract] [Full Text] [Related]

  • 10. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
    Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M.
    N Engl J Med; 1995 Feb 02; 332(5):292-7. PubMed ID: 7816064
    [Abstract] [Full Text] [Related]

  • 11. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
    Caesar I, Gross V, Roth M, Andus T, Schmidt C, Raedsch R, Weber A, Gierend M, Ewe K, Schölmerich J.
    Z Gastroenterol; 1995 May 02; 33(5):247-50. PubMed ID: 7610691
    [Abstract] [Full Text] [Related]

  • 12. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
    Tremaine WJ, Hanauer SB, Katz S, Winston BD, Levine JG, Persson T, Persson A, Budesonide CIR United States Study Group.
    Am J Gastroenterol; 2002 Jul 02; 97(7):1748-54. PubMed ID: 12135030
    [Abstract] [Full Text] [Related]

  • 13. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, Triadaphyllou G.
    Clin Gastroenterol Hepatol; 2003 Mar 02; 1(2):122-8. PubMed ID: 15017504
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ.
    N Engl J Med; 1997 Oct 09; 337(15):1029-35. PubMed ID: 9321530
    [Abstract] [Full Text] [Related]

  • 16. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E, International Budesonide-Mesalazine Study Group.
    Am J Gastroenterol; 2002 Mar 09; 97(3):649-53. PubMed ID: 11922560
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab for active Crohn's disease.
    Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S, Natalizumab Pan-European Study Group.
    N Engl J Med; 2003 Jan 02; 348(1):24-32. PubMed ID: 12510039
    [Abstract] [Full Text] [Related]

  • 18. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.
    Gastroenterology; 2007 May 02; 132(5):1672-83. PubMed ID: 17484865
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.